Home - Products - Angiogenesis - PDGFR - Rinucumab

Rinucumab

CAS No. 1569263-06-4

Rinucumab( —— )

Catalog No. M36761 CAS No. 1569263-06-4

Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	687	In Stock
10MG	937	In Stock
25MG	1416	In Stock
50MG	1832	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Rinucumab
Note

Research use only, not for human use.
Brief Description

Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.
Description

Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

PDGFR
Recptor

PDGFR
Research Area

——
Indication

——

Chemical Information

CAS Number

1569263-06-4
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Megan Cully, et al. Deal watch: Novartis eyes vision-enhancing therapy for macular degeneration. Nat Rev Drug Discov. 2014 Jul;13(7):487.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

CT52923

CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor.
TSU-68

TSU-68 (Orantinib, SU6668) is a small-molecule, ATP-competitiv inhibitor of angiogenic related RTKs KDR, PDGFRβ, FGFR1.
Sunitinib

A multi-targeted RTK inhibitor that targets VEGFR2 (Flk-1) and PDGFRβ with Ki of 8 nM and 9 nM respectively.

Sign In Join Free